26 Oct 2026

France’s draft 2027 Social Security Financing Bill proposes a statutory process for annual reassessment of selected reimbursed medicines and therapeutic classes. The measure, in Article 30, remains unapproved after the National Assembly rejected the bill at first reading on 23 October.

The French National Authority for Health (Haute Autorité de santé, HAS) already reassesses medicines when new evidence or therapeutic alternatives justify reviewing clinical benefit. The proposal would establish an explicit recurring route, allowing HAS or health ministers to identify medicines for reassessment each year.

Reviews could consider advances in scientific evidence, changes in treatment strategy, new alternatives and relevant health-economic information. HAS could request further evidence from the marketing authorisation holder for another reassessment within five years. Failure to submit the requested data could lead to a penalty of up to 10% of the medicine’s annual turnover.

Where HAS concluded that continued reimbursement was no longer justified, the ministers responsible for health and social security would have six months to publish how they intended to respond. The provision would not automatically remove a medicine from reimbursement following an adverse assessment.

This proposed legislative procedure is distinct from the lifecycle price reviews introduced through the new CEPS-industry agreement. It would introduce a more systematic means of revisiting whether established medicines should remain publicly funded, with potential consequences for evidence requirements and subsequent reimbursement decisions.

Source: French National Assembly
Link: Rejet, en première lecture, du projet de loi de financement de la sécurité sociale pour 2027 (Rejection at first reading of the 2027 Social Security Financing Bill)
Date: 23 October 2026

Source: French National Assembly
Link: Projet de loi de financement de la sécurité sociale pour 2027, n° 3211 (2027 Social Security Financing Bill, No. 3211)
Date: 1 October 2026